Heparin-induced thrombocytopenia

Journal of the American College of Cardiology

Volumn 31, Issue 7, 1998, Pages 1449-1459

  Brieger, David B ^a   Mak, Koon Hou ^a   Kottke Marchant, Kandice ^a   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CHONDROITIN SULFATE; DANAPAROID; GLYCOSAMINOGLYCAN POLYSULFATE; HEPARIN; HIRUDIN; ILOPROST; LOW MOLECULAR WEIGHT HEPARIN; STREPTOKINASE; THROMBOCYTE FACTOR 4; UROKINASE; WARFARIN;

BLEEDING; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVIEW; SKIN NECROSIS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM;

ANTICOAGULANTS; ANTITHROMBINS; BLOOD COAGULATION; ENDOTHELIUM, VASCULAR; HEPARIN; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOCYTOPENIA;

EID: 0031776402     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00134-X     Document Type: Review

References (141)

1. Ware J., Salzman E. Use of heparin in treatment of thromboembolic disorders. Lane D., Lindahl U. Heparin: Chemical and Biological Properties, Clinical Applications. 1989;475-494 Edward Arnold, London, Melbourne, Auckland.
2. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary disease. Lancet. 336:1990;827-830.
3. Theroux P., Quimet H., McCans J., et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 319:1988;1105-1111.
4. Granger C.B., Hirsh J.H., Califf R.M., et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction results from the GUSTO-1 trial . Circulation. 93:1996;870-878.
5. Hirsh J., Fuster V. Guide to anticoagulant therapy. Part 1: Heparin . Circulation. 89:1994;1449-1468.
6. Chong B.H. Heparin-induced thrombocytopenia. Aust N Z J Med. 22:1992;145-152.
7. Warkentin T.E., Levine M.N., Hirsh J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 332:1995;1330-1335.
8. Schmitt B.P., Adelman B. Heparin-associated thrombocytopenia a critical review and pooled analysis . Am J Med Sci. 305:1993;208-215.
9. Warkentin T.E., Kelton J.G. Heparin and platelets. Hematol Oncol Clin North Am. 4:1990;243-264.
10. Chong B.H. Heparin-induced thrombocytopenia. Br J Haematol. 89:1995;431-439.
11. Doty J.R., Alving B.M., McDonnell D.E., Ondra S.L. Heparin-associated thrombocytopenia in the neurosurgical patient. Neurosurgery. 19:1986;69-72.
12. Brushwood D.B. Hospital liable for allergic reaction to heparin used in injection flush. Am J Hosp Pharm. 49:1992;1491-1492.
13. Rizzoni W.E., Miller K., Rick M., Lotze M.T. Heparin-induced thrombocytopenia and thromboembolism in the postoperative period. Surgery. 103:1987;470-476.
14. Heeger P.S., Backstrom J.T. Heparin flushes and thrombocytopenia [letter]. Ann Intern Med. 105:1986;143.
15. Laster J., Silver D. Heparin-coated catheters and heparin-induced thrombocytopenia. J Vasc Surg. 7:1988;667-672.
16. Kapsch D., Silver D. Heparin-induced thrombocytopenia with thrombosis and hemorrhage. Arch Surg. 116:1981;1423-1427.
17. Makhoul R.G., Greenberg C.S., McCann R.L. Heparin-associated thrombocytopenia and thrombosis a serious clinical problem and potential solution . J Vasc Surg. 4:1986;522-528.
18. Cimo P.L., Moake J.L., Weinger R.S., Ben-Menachem Y., Khalil K.G. Heparin-induced thrombocytopenia association with a platelet aggregating factor and arterial thromboses . Am J Hematol. 6:1979;125-133.
19. Chang J.C. White clot syndrome associated with heparin-induced thrombocytopenia a review of 23 cases . Heart Lung. 16:1987;403-407.
20. King D.J., Kelton J.G. Heparin-associated thrombocytopenia. Ann Intern Med. 100:1984;535-540.
21. Bell W.R., Royall R.M. Heparin-associated thrombocytopenia a comparison of three heparin preparations . N Engl J Med. 303:1980;902-907.
22. Powers P.J., Kelton J.G., Carter C.J. Studies on the frequency of heparin associated thrombocytopenia. Thromb Res. 33:1984;439-443.
23. Stead R.B., Schafer A.I., Rosenberg R.D., Handin R.I., Josa M., Khuri S.F. Heterogeneity of heparin lots associated with thrombocytopenia and thromboembolism. Am J Med. 77:1984;185-188.
24. Vitoux J.F., Roncato M., Hourdebaigt P., Aiach M., Fiessinger J.-N. Heparin-induced thrombocytopenia and pentosan polysulfate treatment with a low molecular weight heparin despite in vitro platelet aggregation . Thromb Haemost. 55:1985;294-295.
25. Greinacher A., Michels I., Schafer M., Kiefel V., Mueller-Eckhardt C. Heparin-associated thrombocytopenia in a patient treated with polysulphated chondroitin sulphate evidence for immunological crossreactivity between heparin and polysulphated glycosaminoglycan . Br J Haematol. 81:1992;252-254.
26. Silver D., Kapsch D.N., Tsoi E.K.M. Heparin-induced thrombocytopenia, thrombosis and hemorrhage. Ann Surg. 198:1983;301-306.
27. Van Der Weyden M.B., Hunt H., McGrath K., et al. Delayed-onset heparin-induced thrombocytopenia. Med J Aust. 2:1983;132-135.
28. Boshkov L.K., Warkentin T.E., Hayward C.P.M., Andrew M., Kelton J.G. Heparin-induced thrombocytopenia and thrombosis clinical and laboratory studies . Br J Haematol. 84:1993;322-328.
29. Warkentin T.E., Kelton J.G. Heparin-induced thrombocytopenia. Prog Hemost Thromb. 10:1991;1-34.
30. Warkentin T.E., Kelton J.G. Interaction of heparin with platelets, including heparin-induced thrombocytopenia. Bounameaux H. Low-molecular-weight heparins in prophylaxis and therapy of thromboembolic diseases. 1994;75-127 Marcel Dekker, New York, Basel, Hong Kong.
31. Warkentin T.E., Kelton J.G. A fourteen year study of heparin induced thrombocytopenia. Am J Med. 101:1996;502-507.
32. Amiral J., Wolf M., Fischer A.-M., Boyer-Neumann C., Vissac A.-M., Meyer D. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol. 92:1996;954-959.
33. Amiral J., Bridey F., Dreyfus M., et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost. 68:1992;95-96.
34. Gruel Y., Boizard-Boval B., Wautier J.L. Further evidence that alpha-granule components such as platelet factor 4 are involved in platelet-IgG-heparin interactions during heparin-associated thrombocytopenia. Thromb Haemost. 70:1993;374-375.
35. Horne M.K., Alkins B.R. Importance of PF4 in heparin-induced thrombocytopenia confirmation with gray platelets . Blood. 85:1995;1408-1409.
36. Kelton J.G., Smith J.W., Warkentin T.E., Hayward C.P.M., Denomme G.A., Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood. 83:1994;3232-3239.
37. Greinacher A., Amiral J., Dummel V., Vissac A., Kiefel V., Mueller-Eckhardt C. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion. 34:1994;381-385.
38. Platell C.F.E., Tan E.G.C. Hypersensitivity reactions to heparin delayed onset thrombocytopenia and necrotizing skin lesions . Aust N Z J Surg. 56:1986;621-623.
39. Nelson J.C., Lerner R.G., Goldstein R., Cagin N.A. Heparin-induced thrombocytopenia. Arch Intern Med. 138:1978;548-552.
40. Gruel Y., Lang M., Darnige L., et al. Fatal effect of re-exposure to heparin after previous heparin-associated thrombocytopenia and thrombosis. Lancet. 336:1990;1077-1078.
41. Visentin G.P., Ford S.E., Scott J.P., Aster R.H. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 93:1994;81-88.
42. Chong B.H., Pilgrim R.L., Cooley M.A., Chesterman C.N. Increased expression of platelet IgG Fc receptors in immune heparin-induced thrombocytopenia. Blood. 81:1993;988-993.
43. Burgess A.K., Lindeman R., Chesterman C.N., Chong B.H. Single amino acid mutation of Fcγ receptor is associated with the development of heparin-induced thrombocytopenia. Br J Haematol. 91:1995;761-766.
44. Chong B.H., Pitney W.R., Castaldi P.A. Heparin-induced thrombocytopenia association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis and platelet aggregation . Lancet. 2:1982;1246-1249.
45. Sheridan D., Carter C., Kelton J.G. A diagnostic test for heparin-induced thrombocytopenia. Blood. 67:1986;27-30.
46. Warkentin T.E., Hayward C.P.M., Boshkov L.K., et al. Sera from patients with heparin-induced thrombocytopenia generate platelet derived microparticles with procoagulant activity an explanation for the thrombotic complications of heparin-induced thrombocytopenia . Blood. 84:1994;3691-3699.
47. Cines D.B., Tomaski A., Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med. 316:1987;581-589.
48. Damus P.S., Hicks M., Rosenberg R.D. A generalized view of heparin's anticoagulant action. Nature. 246:1973;355-357.
49. Laster J., Cikrit D., Walker N., Silver D. The heparin-induced thrombocytopenia syndrome an update . Surgery. 102:1987;763-770.
50. Kappa J.R., Fisher C.A., Berkowitz H.D., Cottrell E.D., Addonizio V.P. Heparin-induced platelet activation in sixteen surgical patients diagnosis and management . J Vasc Surg. 5:1987;101-109.
51. Ramirez-Lassepas M., Cipolle R.J., Rodvold K.A., et al. Heparin-induced thrombocytopenia in patients with cerebrovascular ischaemic disease. Neurology. 34:1984;736-740.
52. Hach-Wunderle V., Kainer K., Krug B., Muller-Berghaus G., Potzsch B. Heparin associated thrombosis despite normal platelet counts. Lancet. 344:1994;469-470.
53. Stanton P.E., Evans J.R., Lefemine A.A., et al. White clot syndrome. South Med J. 81:1988;616-620.
54. Leroy J., Leclerc M.H., Delahousse B., et al. Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216). Semin Thromb Hemost. 11:1985;326-329.
55. Singer R.L., Mannion J.D., Bauer T.L., Armenti F.R., Edie R.N. Complications from heparin-induced thrombocytopenia in patients undergoing cardiopulmonary bypass. Chest. 104:1993;1036-1040.
56. Towne J.B., Bernhard V.M., Hussey C., Garancis J.C. White clot syndrome peripheral vascular complication of heparin therapy . Arch Surg. 114:1979;372-377.
57. Thomas D., Block A.J. Thrombocytopenia, cutaneous necrosis, and gangrene of the upper and lower extremities in a 35-year-old man. Chest. 102:1992;1578-1580.
58. Baird R.A., Convery F.R. Arterial thromboembolism in patients receiving systemic heparin therapy a complication associated with heparin-induced thrombocytopenia . J Bone Joint Surg. 59A:1977;1061-1064.
59. Walls J.T., Curtis J.J., Silver D., Boley T.M., Schmaltz R.A., Nawarawong N. Heparin-induced thrombocytopenia in open heart surgical patients sequelae of late recognition . Ann Thorac Surg. 53:1992;787-791.
60. Guittard M., Pradalier A., Vincent D., Dry J. Thrombose intraventriculaire droite et thrombopenie a l-heparine [letter]. Presse Med. 17:1988;871.
61. Arthur C.K., Grant S.J.B., Murray W.K., Isbister J.P., Stiel J.N., Lauer C.S. Heparin associated acute adrenal insufficiency. Aust N Z J Med. 15:1985;454-455.
62. Van Damme H., Damas P., David J.L., Limet R. Heparin-induced thrombocytopenia a case report . Angiology. 41:1990;1075-1081.
63. Rhodes G.R., Dixon R.H., Silver D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynaecol Obstet. 136:1973;409-416.
64. Gallus A.S., Goodall K.T., Tillett J., Jackaman J., Wycherley A. The relative contribution of antithrombin III during heparin treatment, and of clinically recognisable risk factors, to early recurrence of venous thromboembolism. Thromb Res. 46:1987;539-553.
65. Sandler R.M., Seifer D.B., Morgan K., et al. Heparin-induced thrombocytopenia and thrombosis detection and specificity of a platelet aggregating IgG . Am J Clin Pathol. 83:1985;760-764.
66. Weismann R.E., Tobin R.W. Arterial embolism occurring during systemic heparin therapy. Arch Surg. 76:1958;219-227.
67. White P.W., Sadd J.R., Nensel R.E. Thrombotic complications of heparin therapy, including six cases of heparin-induced skin necrosis. Ann Surg. 190:1978;595-608.
68. Ulrick P.J., Manoharan A. Heparin-induced skin reaction. Med J Aust. 140:1984;287-289.
69. Hartman A.R., Hood R.M., Anagnostopoulos C.E. Phenomenon of heparin-induced thrombocytopenia associated with skin necrosis. J Vasc Surg. 7:1988;781-784.
70. Fowlie J., Stanton P.D., Anderson J.R. Heparin-associated skin necrosis. Postgrad Med J. 66:1990;573-575.
71. Ansell J., Deykin D. Heparin-induced thrombocytopenia and recurrent thromboembolism. Am J Hematol. 8:1980;325-332.
72. Padilla A., Gray E., Pepper D.S., Barrowcliffe T.W. Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the presence and absence of platelet factor 4 (PF4). Br J Haematol. 82:1992;406-413.
73. Bode A.P., Eick L. Lysed platelets shorten the activated coagulation time (ACT) of heparinized blood. Am J Clin Pathol. 91:1989;430-434.
74. Kapsch D.N., Adelstein E.H., Rhodes G.R., Silver D. Heparin-induced thrombocytopenia, thrombosis, and hemorrhage. Surgery. 86:1979;148-155.
75. Lynch D.M., Howe S.E. Heparin-associated thrombocytopenia antibody binding specificity to platelet antigens . Blood. 66:1985;1176-1181.
76. Souid F., Pourria J.L., Le Roux G., Hoang P. Adrenal haemorrhagic necrosis related to heparin-associated thrombocytopenia. Crit Care Med. 19:1991;297-299.
77. Bleasel J.F., Rasko J.E.J., Rickard K.A., Richards G. Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome. Med J Aust. 157:1992;192-193.
78. Malcolm I.D., Wigmore T.A. Thrombocytopenia induced by low-dose subcutaneous heparin [letter]. Lancet. 1:1978;444.
79. Johnson R.A., Lazarus K.H., Henry D.H. Heparin-induced thrombocytopenia a prospective study . Am J Hematol. 17:1984;349-353.
80. Gallus A.S., Goodall K.T., Beswick W., Chesterman C.N. Heparin-associated thrombocytopenia case report and prospective study . Aust N Z J Med. 10:1980;25-31.
81. Green D., Harris K., Reynolds N., Roberts M., Patterson R. Heparin immune thrombocytopenia evidence for a heparin-platelet complex as the antigenic determinant . J Lab Clin Med. 91:1978;167-175.
82. Harrington R.A., Sane D.C., Califf R.M., et al. Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol. 23:1994;891-898.
83. Hanson E.C., Levine F.H. Hyperlipoproteinemia as a significant risk factor for pulmonary embolism in patients undergoing coronary bypass grafting. Ann Thorac Surg. 33:1982;593-598.
84. Gupta B.K., Savage M.P., Brest A.N. Acute myocardial infarction during coronary angioplasty associated with heparin-induced thrombocytopenia. Cathet Cardiovasc Diagn. 35:1995;42-46.
85. Magnani H.N. Heparin-induced thrombocytopenia (HIT) an overview of 230 patients treated with Orgaran (Org 10172) . Thromb Haemost. 70:1993;554-561.
86. Lecrubier C., Conrad J., Horellou M., Khar H., Samama M. Spontaneous platelet aggregation in heparin-treated patients. Acta Haematol. 71:1984;63-65.
87. Gruel Y., Rupin A., Darnige L., et al. Specific quantification of heparin-dependent antibodies for the diagnosis of heparin-associated thrombocytopenia using an enzyme-linked immunosorbent assay. Thromb Res. 62:1991;377-387.
88. Chong B.H., Burgess J., Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost. 69:1993;344-350.
89. Kelton J.G., Sheridan D., Brain H., Powers P.J., Turpie A.G., Carter C.J. Clinical usefulness of testing for a heparin-dependent platelet-aggregating factor in patients with suspected heparin-associated thrombocytopenia. J Lab Clin Med. 103:1984;606-612.
90. Favaloro E.J., Bernal-Hoyos E., Exner T., Koutts J. Heparin-induced thrombocytopenia laboratory investigation and confirmation of diagnosis . Pathology. 24:1992;177-183.
91. Howe S.E., Lynch D.M. An enzyme-linked immunosorbent assay for the evaluation of thrombocytopenia induced by heparin. J Lab Clin Med. 105:1985;554-559.
92. Greinacher A., Michels I., Kiefel V., Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost. 66:1991;734-736.
93. Kelton J.G., Warkentin T.E. Diagnosis of heparin-induced thrombocytopenia still a journey, not yet a destination . Am J Clin Pathol. 104:1995;611-613.
94. 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol. 104:1995;648-654.
95. Visentin G.P., Malik M., Cyganiak K.A., Aster R.H. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes. J Lab Clin Med. 128:1996;376-383.
96. Bauer T.L., Arepally G., Konkle B.A., et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation. 95:1997;1242-1246.
97. Gallus A., Jackaman J., Tillett J., Mills W., Wycherley A. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet. 2:1986;1293-1296.
98. Babcock R.B., Dumper C.W., Scharfman W.B. Heparin-induced immune thrombocytopenia. N Engl J Med. 295:1976;237-241.
99. Warkentin T.E., Russett J.I., Johnston M., Kelton J.G. Warfarin treatment of deep vein thrombosis complicating heparin-induced thrombocytopenia (HIT) is a risk factor for initiation of venous limb gangrene report of nine patients implicating the interacting procoagulant effects of the two anticoagulant agents [abstract] . Thromb Haemost. 73:1995;1110.
100. Schiele F., Vuillemenot A., Kramarz P., et al. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol. 50:1995;20-25.
101. Nand S. Hirudin therapy for heparin-associated thrombocytopenia and deep venous thrombosis. Am J Hematol. 43:1993;310-311.
102. Ferguson T.J. Meeting highlights the 1995 European Society of Cardiology . Circulation. 92:1995;2359-2363.
103. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 335:1996;775-782.
104. Antman EM, for the TIMI 9B Investigators. Hirudin in acute myocardial infarction: Thrombolysis and thrombin inhibition in Myocardial Infarction (TIMI 9B) trial. Circulation 1996;94:911-21.
105. Brieger D.B., Topol E.J. Hirudin in acute coronary syndromes when cents override good sense . Thromb Thrombolysis. 4:1997;327-329.
106. Matsuo T., Kazuomi K., Chikahira Y., Nakao K., Yamada T. Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor. Br J Haematol. 82:1992;627-629.
107. Lewis B.E., Walenga J.M., Wallis D.E. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Haemost. 23:1997;197-202.
108. Gouault-Heilmann M., Huet Y., Adnot S., et al. Low molecular weight heparin fractions as an alternative therapy in heparin-induced thrombocytopenia. Haemostasis. 17:1987;134-140.
109. Greinacher A., Michels I., Mueller-Eckhardt C. Heparin-associated thrombocytopenia the antibody is not heparin specific . Thromb Haemost. 67:1992;545-549.
110. Ramakrishna R., Manoharan A., Kwan Y.L., Kyle P.W. Heparin-induced thrombocytopenia cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran) . Br J Haematol. 91:1995;736-738.
111. Meuleman D.G. Orgaran (Org 10172) its pharmacologic profile in experimental models . Haemostasis. 22:1992;58-65.
112. Chong B.H., Ismail F., Cade J., Gallus A., Gordon S., Chesterman C.N. Heparin-induced thrombocytopenia studies with a new low molecular weight heparinoid, Org 10172 . Blood. 73:1989;1592-1596.
113. Bachmann F., Leyvraz P. Low molecular weight heparins for the prevention of venous thromboembolism following orthopedic surgery. Bounameaux H. Low Molecular Weight Heparins in Prophylaxis and Therapy of Thromboembolic Diseases. 1994;187-212 Marcel Dekker, New York.
114. de Valk H.W., Banga J.D., Wester J.W.J., et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism a randomized controlled trial . Ann Intern Med. 123:1995;1-9.
115. Bell W.R., Pitney W.R., Goodwin J.F. Therapeutic defibrination in the treatment of thrombotic disease. Lancet. 1:1968;490-493.
116. Teasdale S.J., Zulys V.J., Mycyk T., Baird R.J., Glynn M.F.X. Ancrod anticoagulation for cardiopulmonary bypass in heparin-induced thrombocytopenia and thrombosis. Ann Thorac Surg. 48:1989;712-713.
117. Demers C., Ginsberg J.S., Brill-Edwards P., et al. Rapid anticoagulation using ancrod for heparin induced thrombocytopenia. Blood. 78:1991;2194-2197.
118. Cole C.W., Fournier L.M., Bormanis J. Heparin-associated thrombocytopenia and thrombosis optimal therapy with ancrod . Can J Surg. 33:1990;207-210.
119. AbuRahma A.F., Boland J.P., Witsberger T. Diagnostic and therapeutic strategies of white clot syndrome. Am J Surg. 162:1991;175-179.
120. Laster J., Elfrink R., Silver D. Reexposure to heparin of patients with heparin-associated antibodies. J Vasc Surg. 9:1989;677-682.
121. Chong B.H., Castaldi P.A. Heparin-induced thrombocytopenia further studies of the effects of heparin-dependent antibodies on platelets . Br J Haematol. 64:1986;347-354.
122. 2 synthesis and the extent of platelet granule release in two patients . J Vasc Surg. 9:1989;574-579.
123. Schillinger E., Krais T., Lehman M., Stock G. Iloprost. Scriabine A. New Cardiovascular Drugs. 1986;209-231 Raven Press, New York.
124. Sobel M., Adelman B., Szentpetery S., Hoffman M., Posner M.P., Jenvey W. Surgical management of heparin-associated thrombocytopenia strategies in the treatment of venous and arterial thromboembolism . J Vasc Surg. 8:1988;395-401.
125. Kappa J.R., Fisher C.A., Todd B., et al. Intraoperative management of patients with heparin-induced thrombocytopenia. Ann Thorac Surg. 49:1990;714-723.
126. Gruel Y., Lermusiaux P., Lang M., et al. Usefulness of antiplatelet drugs in the management of heparin-associated thrombocytopenia and thrombosis. Ann Vasc Surg. 5:1991;552-555.
127. Mak K.-H., Kottke-Marchand K., Brooks L.M., Apheart K.L., Topol E.J. Potential value of platelet GPIIb/IIIa antagonist for treating heparin-induced thrombocytopenia (HIT) [abstract]. J Am Coll Cardiol. 27:(Suppl A):1996;316A.
128. Reverter J.C., Beguin S., Kessels H., Kumar R., Hemker H.C., Coller B.S. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. J Clin Invest. 98:1996;863-874.
129. Fareed J., Yang L., Hoppensteadt D., Koza M., Walenga J.M., Welzel D. Glycoprotein IIb/IIIa inhibitors can prevent heparin mediated platelet activation in heparin-induced thrombocytopenia [abstract]. Circulation. 94:(Suppl I):1996;I-228.
130. Kelton J.G., Sheridan D., Santos A., et al. Heparin-induced thrombocytopenia laboratory studies . Blood. 72:1988;925-930.
131. Greinacher A., Liebenhoff U., Kiefel V., Presek P., Mueller-Eckhardt C. Heparin-associated thrombocytopenia: the effects of various intravenous IgG preparations on antibody mediated platelet activation - a possible new indication for high dose i.v. IgG. Thromb Haemost. 71:1994;641-645.
132. Clifton G.D., Smith M.D. Thrombolytic therapy in heparin-associated thrombocytopenia with thrombosis. Clin Pharm. 5:1986;597-601.
133. Mehta D.P., Yoder E.L., Appel J., Bergsman K.L. Heparin-induced thrombocytopenia and thrombosis: reversal with streptokinase. A case report and review of the literature. Am J Hematol. 36:1991;275-279.
134. Cohen J.I., Cooper M.R., Greenberg C.S. Streptokinase therapy of pulmonary emboli with heparin-associated thrombocytopenia. Arch Intern Med. 145:1985;1725-1726.
135. Feissinger J.N., Aiach M., Roncato M., Debure C., Gaux J.C. Critical ischemia during heparin-induced thrombocytopenia treatment by intra-arterial streptokinase . Thromb Res. 33:1984;235-238.
136. Bouvier J.L., Lefevre P., Villain P., et al. Treatment of serious heparin-induced thrombocytopenia by plasma exchange report on 4 cases . Thromb Res. 51:1988;335-336.
137. Nand S., Robinson J.A. Plasmapheresis in the management of heparin-associated thrombocytopenia with thrombosis. Am J Hematol. 28:1988;204-206.
138. Brady J., Riccio J.A., Yumen O.H., Makary A.Z., Greenwood S.M. Plasmapheresis a therapeutic option in the management of heparin-associated thrombocytopenia with thrombosis . Am J Clin Pathol. 96:1991;394-397.
139. Vender J.S., Matthew E.B., Silverman I.M., Konowitz H., Dau P.C. Heparin-associated thrombocytopenia alternative managements . Anesth Analg. 65:1986;520-522.
140. Frame J.N., Mulvey K.P., Phares J.C., Anderson M.J. Correction of severe heparin-associated thrombocytopenia with intravenous immunoglobulin. Ann Intern Med. 111:1989;946-947.
141. Olinger G.N., Hussey C.V., Olive J.A., Malik M.I. Cardiopulmonary bypass for patients with previously documented heparin-induced platelet aggregation. J Thorac Cardiovasc Surg. 87:1984;673-677.